Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 70

1.

Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells.

Israel MA, Yuan SH, Bardy C, Reyna SM, Mu Y, Herrera C, Hefferan MP, Van Gorp S, Nazor KL, Boscolo FS, Carson CT, Laurent LC, Marsala M, Gage FH, Remes AM, Koo EH, Goldstein LS.

Nature. 2012 Jan 25;482(7384):216-20. doi: 10.1038/nature10821.

2.

The curious case of phenocopies in families with genetic Parkinson's disease.

Klein C, Chuang R, Marras C, Lang AE.

Mov Disord. 2011 Aug 15;26(10):1793-802. doi: 10.1002/mds.23853. Epub 2011 Jul 6. Review.

PMID:
21735483
3.

The regulation and physiology of mitochondrial proton leak.

Divakaruni AS, Brand MD.

Physiology (Bethesda). 2011 Jun;26(3):192-205. doi: 10.1152/physiol.00046.2010. Review.

4.

Development of histocompatible primate-induced pluripotent stem cells for neural transplantation.

Deleidi M, Hargus G, Hallett P, Osborn T, Isacson O.

Stem Cells. 2011 Jul;29(7):1052-63. doi: 10.1002/stem.662.

5.

Mitochondrial Parkin recruitment is impaired in neurons derived from mutant PINK1 induced pluripotent stem cells.

Seibler P, Graziotto J, Jeong H, Simunovic F, Klein C, Krainc D.

J Neurosci. 2011 Apr 20;31(16):5970-6. doi: 10.1523/JNEUROSCI.4441-10.2011.

6.

Mutations in PINK1 and Parkin impair ubiquitination of Mitofusins in human fibroblasts.

Rakovic A, Grünewald A, Kottwitz J, Brüggemann N, Pramstaller PP, Lohmann K, Klein C.

PLoS One. 2011 Mar 8;6(3):e16746. doi: 10.1371/journal.pone.0016746.

7.

Identifying consensus disease pathways in Parkinson's disease using an integrative systems biology approach.

Edwards YJ, Beecham GW, Scott WK, Khuri S, Bademci G, Tekin D, Martin ER, Jiang Z, Mash DC, ffrench-Mullen J, Pericak-Vance MA, Tsinoremas N, Vance JM.

PLoS One. 2011 Feb 22;6(2):e16917. doi: 10.1371/journal.pone.0016917.

8.

A functionally characterized test set of human induced pluripotent stem cells.

Boulting GL, Kiskinis E, Croft GF, Amoroso MW, Oakley DH, Wainger BJ, Williams DJ, Kahler DJ, Yamaki M, Davidow L, Rodolfa CT, Dimos JT, Mikkilineni S, MacDermott AB, Woolf CJ, Henderson CE, Wichterle H, Eggan K.

Nat Biotechnol. 2011 Mar;29(3):279-86. doi: 10.1038/nbt.1783. Epub 2011 Feb 3.

9.

Bioenergetics of neurons inhibit the translocation response of Parkin following rapid mitochondrial depolarization.

Van Laar VS, Arnold B, Cassady SJ, Chu CT, Burton EA, Berman SB.

Hum Mol Genet. 2011 Mar 1;20(5):927-40. doi: 10.1093/hmg/ddq531. Epub 2010 Dec 7.

10.

Mitochondrial impairment in patients with Parkinson disease with the G2019S mutation in LRRK2.

Mortiboys H, Johansen KK, Aasly JO, Bandmann O.

Neurology. 2010 Nov 30;75(22):2017-20. doi: 10.1212/WNL.0b013e3181ff9685.

PMID:
21115957
11.

The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease.

Cookson MR.

Nat Rev Neurosci. 2010 Dec;11(12):791-7. doi: 10.1038/nrn2935. Epub 2010 Nov 19. Review.

12.

Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1.

Guzman JN, Sanchez-Padilla J, Wokosin D, Kondapalli J, Ilijic E, Schumacker PT, Surmeier DJ.

Nature. 2010 Dec 2;468(7324):696-700. doi: 10.1038/nature09536. Epub 2010 Nov 10. Erratum in: Nature. 2015 May 21;521(7552):380.

13.

Genetic analysis of pathways to Parkinson disease.

Hardy J.

Neuron. 2010 Oct 21;68(2):201-6. doi: 10.1016/j.neuron.2010.10.014. Review.

14.

Pathogenic lysosomal depletion in Parkinson's disease.

Dehay B, Bové J, Rodríguez-Muela N, Perier C, Recasens A, Boya P, Vila M.

J Neurosci. 2010 Sep 15;30(37):12535-44. doi: 10.1523/JNEUROSCI.1920-10.2010.

15.

Bafilomycin A1 activates respiration of neuronal cells via uncoupling associated with flickering depolarization of mitochondria.

Zhdanov AV, Dmitriev RI, Papkovsky DB.

Cell Mol Life Sci. 2011 Mar;68(5):903-17. doi: 10.1007/s00018-010-0502-8. Epub 2010 Sep 6.

16.

Inhibitors of leucine-rich repeat kinase-2 protect against models of Parkinson's disease.

Lee BD, Shin JH, VanKampen J, Petrucelli L, West AB, Ko HS, Lee YI, Maguire-Zeiss KA, Bowers WJ, Federoff HJ, Dawson VL, Dawson TM.

Nat Med. 2010 Sep;16(9):998-1000. doi: 10.1038/nm.2199. Epub 2010 Aug 22.

17.

Differentiation of human ES and Parkinson's disease iPS cells into ventral midbrain dopaminergic neurons requires a high activity form of SHH, FGF8a and specific regionalization by retinoic acid.

Cooper O, Hargus G, Deleidi M, Blak A, Osborn T, Marlow E, Lee K, Levy A, Perez-Torres E, Yow A, Isacson O.

Mol Cell Neurosci. 2010 Nov;45(3):258-66. doi: 10.1016/j.mcn.2010.06.017. Epub 2010 Jul 24.

18.

Effect of endogenous mutant and wild-type PINK1 on Parkin in fibroblasts from Parkinson disease patients.

Rakovic A, Grünewald A, Seibler P, Ramirez A, Kock N, Orolicki S, Lohmann K, Klein C.

Hum Mol Genet. 2010 Aug 15;19(16):3124-37. doi: 10.1093/hmg/ddq215. Epub 2010 May 27.

19.

Clinical and demographic characteristics of PINK1 mutation carriers--a meta-analysis.

Kasten M, Weichert C, Lohmann K, Klein C.

Mov Disord. 2010 May 15;25(7):952-4. doi: 10.1002/mds.23031. No abstract available.

PMID:
20461815
20.

Parkinson's disease: insights from pathways.

Cookson MR, Bandmann O.

Hum Mol Genet. 2010 Apr 15;19(R1):R21-7. doi: 10.1093/hmg/ddq167. Epub 2010 Apr 26. Review.

Items per page

Supplemental Content

Write to the Help Desk